| IPO Company Profile |
| Current Quote | News | SEC Filings | Peer IPO Companies |
| RiboGene, Inc. |
| 21375 Cabot Boulevard, Hayward, CA 94545 * (510) 732-5551 |
| The company is a drug discovery company focused on the identification of novel leads and the development of potential drug candidates for the treatment of infectious diseases. |
| Manager | Tier | Phone |
| Everen Securities, Inc. | Lead Manager | (312) 574-6859 |
| Cruttenden Roth Incorporated | Co-manager | (800) 678-9147 |
| Gruntal & Co | Co-manager | (212) 225-4334 |
| AMEX: | RBO | Service: | SIC 8731 | |
| Type of Shares: | Common Shares | Filing Date: | 10/27/97 | |
| U.S. Shares: | 2,300,000 | Offer Date: | 5/27/98 | |
| Non-U.S. Shares: | 0 | Filing Range: | $5.00 - $7.00 | |
| Primary Shares: | 2,300,000 | Offer Price: | $7.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.56 | |
| Offering Amount: | $13,800,000 | Selling: | $0.30 | |
| Expenses: | $750,000 | Reallowance: | $0.10 | |
| Post-IPO Shares: | 6,847,117 | |||
| Employees: | 28 |
| Issuer's Law Firm: | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm: | Skadden, Arps, Slate, Meagher & Flom |
| Registrar/Transfer Agent: | American Stock Transfer & Trust Co |
| Auditor: | Ernst & Young |
Dollar amounts in U.S. millions except for per share data | |||||
| 6 Month Ending Financials | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Audited Income | Balance Sheet | ||
| 12/31/96 | 6/30/97 | 6/30/96 | 6/30/97 | ||
| Revenue: | $2.09 | $1.58 | $0.69 | Assets: | $4.00 |
| Net Income: | -$3.86 | -$1.26 | -$2.61 | Curr Assets: | $3.58 |
| EPS: | -$0.75 | -$0.23 | Liabilities: | $3.10 | |
| Prior EPS: | Curr Liab: | $2.71 | |||
| Cash Flow/Oper: | -$3.14 | -$1.74 | -$2.50 | Equity: | $0.90 |
| Cash Flow/Fin: | $3.24 | $3.06 | $3.31 | Cash: | $3.28 |
| Cash Flow/Inv: | -$0.01 | -$0.90 | $0.00 | Working Cap: | $0.87 |
| Competition |
| The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Many of the drugs which the Company is developing will be competing with existing therapies. In addition, a number of companies are pursuing the development of pharmaceuticals which target the same diseases and conditions the Company is targeting, using technology similar to the RiboGene technology, as well as alternative discovery technologies, including antisense, gene therapy and genomics. The Company faces competition from pharmaceutical and biotechnology companies both in the United States and abroad. Many of the Company's competitors, particularly large pharmaceutical companies, have substantially greater financial, technical and human resources than the Company. In addition, unlike the Company, many of these competitors have experience in undertaking preclinical studies and clinical trials of new pharmaceutical products, obtaining the necessary regulatory approvals and manufacturing and marketing products. In addition, academic institutions, government agencies, and other public and private organizations conducting research may seek patent protection with respect to potentially competing products or technologies and may establish exclusive collaborative or licensing relationships with competitors of the Company. The Company believes that its ability to compete is dependent, in part, upon its abilities to create and maintain scientifically advanced technology and to develop and commercialize pharmaceutical products based on this technology, as well as its ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary technology or processes and secure sufficient capital resources for the expected substantial time period between technological conception and commercial sales of products based upon the Company's technology. |
| Business Plan |
| The Company's objective is to discover and develop novel antiinfective drugs. To achieve this objective, the key elements of the Company's strategy are to: (I) Exploit expertise in pathgen specific translation mechanisms, (ii) Develop novel antiinfectives which target drug resistant pathogens, (iii) Leverage platform technology over multiple indications and multiple targets, (iv) Establish collaborative relationship and (v) Maintain and enhance propreitary position. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for expansion of chemistry capabilities, expansion and advancement of drug discovery programs, facility relocation, repayment of a secured note and related obligations and working capital and general corporate purposes. |
| Name of Shareholder | % Owned Before | % Owned After |
| Dr. LindsayRosenwald | 0.17 | 0.16 |
| Kleiner Perkins Caufield & Byers V, a California Limited Partnership | 0.14 | 0.08 |
| CW Ventures II, L.P. | 0.12 | 0.07 |
| Entities affiliated with the Aries Trust | 0.12 | 0.11 |
| Dr. Jesse I. Treu | 0.10 | 0.06 |
| Domain Partners II, L.P. | 0.10 | 0.06 |
| Sierra Ventures III | 0.10 | 0.06 |
| Abbot Alboratories | 0.10 | 0.11 |
| Biotechnology Investment Limited | 0.08 | 0.05 |
| Hyline Laboratories, Inc. | 0.08 | 0.05 |
| Oxford Bioscience Partners L.P. | 0.07 | 0.05 |
| Charles J. Casamento | 0.06 | 0.03 |
| Officer Name | Title | Age |
| Charles M. Moehle, Ph.D. | Associate Director of Translational Control Research | 38 |
| Charles Gluchowski, Ph.D. | Director of Drug Discovery | 42 |
| Charles J. Casamento | President, Chief Executive Officer and Chairman of the Board of Director | 52 |
| Laura S. Lehman, Ph.D. | Vice President of Research | 40 |
| Timothy E. Morris | Vice President, Finance & Administration, Chief Financial Officer and Assistant Secretary | 35 |